Literature DB >> 19497337

Kappa-opioid ligands in the study and treatment of mood disorders.

William A Carlezon1, Cécile Béguin, Allison T Knoll, Bruce M Cohen.   

Abstract

The biological basis of mood is not understood. Most research on mood and affective states has focused on the roles of brain systems containing monoamines (e.g., dopamine, norepinephrine, serotonin). However, it is becoming clear that endogenous opioid systems in the brain may also be involved in the regulation of mood. In this review, we focus on the potential utility of kappa-opioid receptor (KOR) ligands in the study and treatment of psychiatric disorders. Research from our group and others suggests that KOR antagonists might be useful for depression, KOR agonists might be useful for mania, and KOR partial agonists might be useful for mood stabilization. Currently available KOR agents have some unfavorable properties that might be addressed through medicinal chemistry. The development of KOR-selective agents with improved drug-like characteristics would facilitate preclinical and clinical studies designed to evaluate the possibility that KORs are a feasible target for new medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497337      PMCID: PMC2740476          DOI: 10.1016/j.pharmthera.2009.05.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  130 in total

1.  STUDIES ON THE HUMAN ADDICTION LIABILITY OF 2'-HYDROXY-5-9-DIMETHYL-2-(3,3-DIMETHYLALLYL)-6,7-BENZOMORPHAN (WIN 20,228): A WEAK NARCOTIC ANTAGONIST.

Authors:  H F FRASER; D E ROSENBERG
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

2.  Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

Authors:  L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh
Journal:  NIDA Res Monogr       Date:  1998-03

3.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

4.  Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage).

Authors:  R Bücheler; C H Gleiter; P Schwoerer; I Gaertner
Journal:  Pharmacopsychiatry       Date:  2005-01       Impact factor: 5.788

5.  Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell.

Authors:  A L Svingos; E E Colago; V M Pickel
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

Review 6.  The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.

Authors:  Derick E Vergne; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

7.  Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze.

Authors:  Dominique Drapier; Danièle Bentué-Ferrer; Bruno Laviolle; Bruno Millet; Hervé Allain; Michel Bourin; Jean-Michel Reymann
Journal:  Behav Brain Res       Date:  2006-11-13       Impact factor: 3.332

8.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

9.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

10.  Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/cyclic AMP response element-directed gene transcription.

Authors:  M Schwaninger; C Schöfl; R Blume; L Rössig; W Knepel
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

View more
  57 in total

1.  Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors.

Authors:  John W Muschamp; Ashlee Van't Veer; William A Carlezon
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

Review 2.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.

Authors:  Erica J Melief; Mayumi Miyatake; F Ivy Carroll; Cécile Béguin; William A Carlezon; Bruce M Cohen; Sarah Grimwood; Charles H Mitch; Linda Rorick-Kehn; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2011-08-10       Impact factor: 4.436

4.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

5.  Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity.

Authors:  Achla Gupta; Ivone Gomes; Erin N Bobeck; Amanda K Fakira; Nicholas P Massaro; Indrajeet Sharma; Adrien Cavé; Heidi E Hamm; Joseph Parello; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

6.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

7.  Coordinate regulation of noradrenergic and serotonergic brain regions by amygdalar neurons.

Authors:  T A Retson; E J Van Bockstaele
Journal:  J Chem Neuroanat       Date:  2013-05-04       Impact factor: 3.052

8.  Identification of novel functionally selective κ-opioid receptor scaffolds.

Authors:  Kate L White; Alex P Scopton; Marie-Laure Rives; Ruslan V Bikbulatov; Prabhakar R Polepally; Peter J Brown; Terrance Kenakin; Jonathan A Javitch; Jordan K Zjawiony; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

Review 9.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

10.  Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Authors:  Ashlee Van't Veer; Anita J Bechtholt; Sara Onvani; David Potter; Yujun Wang; Lee-Yuan Liu-Chen; Günther Schütz; Elena H Chartoff; Uwe Rudolph; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.